Mean Serum Uric Acid Level Research Articles

Risk factors and diagnostic value for ultrasound-detected tendon monosodium urate crystal deposition in patients with gout

OBJECTIVE To evaluate frequency and patterns, risk factors of MSU (monosodium urate) crystal deposition at lower extremity tendon by ultrasonography in gout patients, and to explore diagnostic value by ultrasonography. METHODS Patients diagnosed with gout and age matched healthy controls had ultrasound scanning of both feet and knees including joints and tendons (achilles, quadriceps, and patellar tendon). Readers who scored the ultrasound scans for MSU crystal deposition were blinded to the patients' clinical diagnoses. Clinical characteristics were compared between positive and negative crystal deposition groups by US, and risk factors of MSU deposition in tendons were analyzed. Diagnostic values of MSU deposition were evaluated by ultrasonography according with positive MSU crystal in synovial fluid or tophi by polarized microscopy. RESULTS Eighty patients and eighty healthy controls were included. Thity-three patients (47.5%) had tophi by physical examination. The achilles tendon was the most commonly involved tendon site 41(51.2%), followed by the quadriceps tendons 22(27.5%), and patella tendon 10(12.5%). There were no MSU deposition in healthy control group at tendon by ultrasonography. Compared with negative MSU deposition at tendon site by ultrasonography, tendon MSU positive patients had longer mean gout duration [(87.3±40.9) months vs. (7.7±2.6) months, P=0.001];higher frequency of gout flare [2(1, 2) /year vs. 1(1, 1) /year, P=0.001]; higher BMI [(26.3±2.5) kg/m2vs. (23.3±2.1) kg/m2, P=0.05]. Also, the mean serum uric acid and creatinine levels were higher in tendon MSU positive group [(584.6±87.6) μmol/L vs. (460.4±96.7) μmol/L, P=0.001] and [(90.9±33.3) μmol/L vs. (70.6±40.2) μmol/L, P=0.02] separately. Logistic regression analysis showed gout duration and flare frequency were independent risk factors for MSU deposition at tendon by ultrasonography (P < 0.01). Joint or tophi aspirations were performed in all the eighty gout patients, and positive MSU crystals in synovial fluid analysis by polarized microscopy were defined as the golden standard of gout diagnosis. When compared with the golden standard, the sensitivity and specificity were 94.0% and 78.0% separately for MSU deposition at tendon by ultrasonography. CONCLUSION Tendon involvement at the lower extremity tendons in gout is very common. Long gout disease duration and high frequency of gout flare are both independent risk factors of tendon MSU deposition by ultrasonography. Ultrasonography had good sensitivity and specificity for detecting tendinous tophi and aggregates.

Effect of bempedoic acid on uric acid and gout in 3621 patients with hypercholesterolemia: pooled analyses from phase 3 trials

Abstract Background Bempedoic acid (BA), an oral ATP-citrate lyase inhibitor, significantly lowers low-density lipoprotein cholesterol levels in patients with hypercholesterolemia. In clinical trials of BA, small mean increases in uric acid have been reported. BA weakly inhibits organic anion transporter 2 (OAT2) in vitro, which may account for small elevations in serum uric acid. Purpose To assess uric acid levels and incidence of gout with BA treatment. Methods Data were pooled from 4 randomized (2:1), double-blind studies of BA (180 mg daily) vs placebo for 12 weeks to 52 weeks in patients with hypercholesterolemia on stable background lipid-lowering therapy. Safety assessments included adverse events of special interest (elevation in uric acid levels, gout) and laboratory assessments. Results A total of 2424 patients treated with BA and 1197 patients on placebo were included in this analysis. Mean (SD) baseline uric acid levels were 6.0 (1.4) mg/dL for both groups. History of gout was reported by 5.2% (127/2424) and 5.8% (69/1197) in the BA and placebo groups, respectively. At week 12, mean (SD) serum uric acid levels (% change from baseline) increased from baseline with BA treatment by 0.82 (0.97) mg/dL (14.8%) vs –0.02 (0.82) mg/dL (0.67%) for placebo. Elevations in serum uric acid levels typically occurred within the first 4 weeks of treatment, remained stable during treatment, and returned to baseline after treatment discontinuation. Gout was reported in 1.4% (BA) and 0.4% (placebo) of patients, and hyperuricemia was reported in 1.7% (BA) and 0.6% (placebo) of patients. Other potential clinical consequences of elevated uric acid levels (eg, events associated with nephrolithiasis), were similar between groups (0.7% vs 0.8%). In both groups, patients who reported gout during the studies were more likely to have a medical history of gout or elevated baseline uric acid levels (Table). Few patients discontinued treatment due to gout (n=1, &amp;lt;0.1% [BA]) or uric acid increases (n=2, &amp;lt;0.1% [BA]). Conclusion Mean increases in uric acid levels were small, remained stable while patients continued to receive treatment, were infrequently associated with AEs, and were reversible on discontinuation of BA Funding Acknowledgement Type of funding source: Private company. Main funding source(s): Esperion Therapeutics funded the research for this study and provided writing support for this abstract. Medical writing assistance was provided by Agnella Izzo Matic, PhD, CMPP, and Kelly M Cameron, PhD, CMPP, of JB Ashtin.

Association of Maternal Hyperuricemia with Post-Spinal Hypotension in Pre-Eclamptic Parturients Undergoing Emergency Cesarean Delivery: a Prospective Observational Study.

Pre-eclampsia is commonly associated with higher serum uric acid levels, which is known to increase vascular tone. A previous retrospective study established a positive correlation between raised serum uric acid levels and reduced incidence of post-spinal hypotension. However, until date, this correlation has not been prospectively evaluated in exclusively pre-eclamptic women. Pre-eclamptic parturients undergoing emergency cesarean delivery under subarachnoid block were included. Sample for measuring serum uric acid level was obtained prior to shifting patients for cesarean delivery. Following spinal anesthesia, we recorded episodes of hypotension (fall of mean arterial pressure more than 20% from baseline values), use of vasopressors, and intraoperative blood loss. Our primary objective was to study the association between maternal hyperuricemia and incidence of post-spinal hypotension. Our secondary objectives included amount of vasopressors administered to maintain targeted mean arterial pressure before delivery of the baby, intraoperative blood loss, and immediate neonatal outcome. A total of 95% parturients had hyperuricemia, with mean serum uric acid level being 6.94 ± 0.9mg/dl. Incidence of post-spinal hypotension was significantly lower in women who had hyperuricemia as compared with those with normal serum uric acid levels (21% vs 75%; p = 0.015). Mean serum uric acid levels were significantly high (p = 0.001) in patients not requiring any vasopressors (7.2 ± 1.2mg/dl) than in those requiring moderate (5.70 ± 0.79mg/dl) to high dose (5.75 ± 0.77mg/dl) of vasopressors. There is a high incidence of hyperuricemia in pre-eclamptic parturients. In these patients, elevated serum uric acid levels is associated with lower incidence of post-spinal hypotension and reduced need of vasopressors to maintain maternal blood pressure within a normal range.

Role of Serum Uric Acid as a Protective Biomarker in Patients with Different Histopathological Grades of Oral Squamous Cell Carcinoma: a Case-Control Study

The antioxidant properties of uric acid may have a protective effect against the formation of oxygen radicals and subsequently against carcinogenicity. The present study aimed at evaluating the serum level of uric acid in patients with oral squamous cell carcinoma (OSCC) with different histopathological grades. In this descriptive-analytical, case-control study, patients with OSCC and healthy controls were selected and matched regarding age and gender. The serum samples were collected from patients (before radiotherapy and chemotherapy) and controls, and their serum uric acid levels were measured enzymatically. Data were analyzed using independent t-test and ANOVA at 0.05 level of significance. The mean serum uric acid level in OSCC patients (4.2 ± 1.5 mg/dL) and healthy controls (4.38 ± 1.22 mg/dL) was not significantly different (P = 0.377). No significant association was noted between the histopathological grade of OSCC and mean serum uric acid (P = 0.781). The serum uric acid level had a direct significant correlation with age in OSCC patients (P < 0.001). The results of this study did not support the role of uric acid as a protective biomarker in OSCC. Further prospective studies are recommended to better elucidate the role of uric acid in the etiology of OSCC.

Association of Serum Uric acid Level and BMI in NAFLD and Healthy Volunteers

A number of studies have reported that exact aetiology of non alcoholic fatty liver disease NAFLD is unknown. Serum uric acid is often incriminated as the etiological agent. Hence this study was taken up explore the role of BMI and serum uric acid in occurrence of NAFLD. A case control study was undertaken to compare the role of serum acid in occurrence of 100 NAFLD cases with 100 healthy volunteers. All the cases and controls were subjected for ultrasound examination and serum uric acid estimation with height and weight. Most of study subjects belonged to 21 – 40 years of age group and females outnumbered males. The Mean BMI among the cases was 25.34 (± 4.44) and controls was 25.12 (± 4.08). Mean serum uric acid level among the cases was 5.68 mg/dl and 4.14 mg/dl among the controls. BMI was more than 25 in 51% of the cases and 54% of the controls. Hyperurecemia was present in 37% of the NAFLD cases and 16% of the healthy volunteers. The author concludes that, the increased serum uric acid was demonstrated as risk factor for non alcoholic fatty liver disease.

Role of serum uric acid in ischemic stroke: A case-control study in Bangladesh.

Increased level of serum uric acid (SUA) is often considered a risk factor for ischemic stroke. This study was conducted to examine the association of SUA level with ischemic stroke and assessed gender-based differences, if any. In this case-control study, neuroimaging-confirmed ischemic stroke patients were recruited as cases within three days of an incident from neurology in-patient department, and as controls, patients without stroke history were recruited from neurology out-patient department. Blood was collected from the respondents of both groups to assess SUA level, lipid profile and oral glucose tolerance test. Binary logistic regression was done for estimating the risks of ischemic stroke. A total of 338 participants were recruited, where 169 were cases and 169 were controls. Around 60 percent respondents of both case and control groups were male. Mean SUA levels for cases and controls were 6.03 (SD 1.84) mg/dl and 4.04 (SD 1.46) mg/dl, respectively. After adjustment for age, tobacco consumption status, diabetes, hypertension, coronary heart disease and dyslipidemia, elevated SUA level was found to be significantly associated with ischemic stroke only in females (OR = 1.49; 95% CI = 1.01-2.19; p<0.05). Overall, each unit increase in SUA level exhibits 25 percent increment in odds of having ischemic stroke (OR = 1.25; 95% CI = 1.02-1.5372; p<0.05). This study concluded that elevated SUA level is significantly associated with the acute phase of an ischemic stroke and gender-specific analysis demonstrates this association only in females.

Distribution Pattern of Serum Uric Acid Level Before and After National Festival Dashain among Patients Visiting Tertiary Hospital, Kathmandu, Nepal

Introduction: Dashain, one of the national festivals in Nepal, celebrated with excessive consumption of high purine content foods, alcoholic and soft beverages. These foods have been associated with higher Serum Uric Acid (SUA) levels leading to hyperuricemia. This study was intended to evaluate the distribution pattern of SUA level a month before and after this festival for two consecutive years.&#x0D; &#x0D; Methods and Materials: The data of 5818 patients visiting Clinical Biochemistry Laboratory, Tribhuvan University Teaching Hospital for SUA test (a month before and after Dashain festival for two consecutive years; 2017 - 2018 A.D.) were collected and analyzed. The statistical analysis was done using SPSS version 21. Continuous variables were expressed as mean ± SD taking 95% confidence interval and p values of &lt;0.05 was considered to be statistically significant. Mann-Whitney U test was used to compare the variables.&#x0D; &#x0D; Results: The mean SUA levels before and after Dashain in two consecutive years were 333.5 ± 112.1 μmol/L and 334.2±114.7 μmol/L in 2017 A.D. and 322.6 ± 103.9μmol/L and 343.2± 111.4 μmol/L in 2018 A.D. There was a significantly elevated level of the mean SUA level after Dashain festival in 2018 among both sexes (p-value &lt;0.05). The age-wise distribution of mean SUA after the Dashain festival was consistent with increasing age among the study population.&#x0D; &#x0D; Conclusion: The study concluded that the Dashain festival has an impact on increasing the SUA level.&#x0D;

Serum Uric Acid Levels among Patients who Died in Recent Year due to Heart Failure with Reduced Ejection Fraction

To examine the relationship of uric acid levels in the last one year with exitus due to heart failure (HF) with clinical and demographic data of patients. Cross-sectional, descriptive study. Bilecik State Hospital, Bilecik, Turkey, from January 2019 to January 2020. The files of 90 people who had exitus due to HF were scanned retrospectively. Demographic data and echocardiography results were recorded. Serum uric acid levels were noted in the 2nd month, 6th month, and 12th month by taking the baseline in the last year before exitus. Mean repeated measurements of uric acid levels that changed over time in patients were compared with ANOVA variance analysis. P <0.05 were accepted as statistically significant. The mean of the left ventricular ejection fraction (LVEF) of the patients was 35.6±6.6%. Mean serum uric acid levels of the patients for one year before excitus were 5.6±2.2 mg/dL (baseline), 6.1±2.3 mg/dL (2th month), 7.1±2.6 mg/dL (6th month), 8.5±3.0 mg/dL (12th month) respectively. There was a statistically significant difference between the basal uric acid mean with the 6th and 12th month uric acid levels both p <0.001. Age and LVEF were not significantly associated with the uric acid increase over time (p=0.250 and p=0.327, respectively) but were statistically different according to gender (p=0.036). In heart failure with reduced ejection fraction (HFrEF), the uric acid level increases progressively towards the last periods before exitus. This increase is more pronounced in men. Key Words: Heart failure, Serum uric acid levels, Prognosis, Gender.

Association between Hyperuricemia and Ischemic Stroke: A Case-Control Study.

To find the association between hyperuricemia and ischemic stroke. Case-control study. Departments of Medicine and Neurology, Mayo Hospital, Lahore, from October 2015 to September 2016. A total of 100 patients were recruited in the study. Fifty cases were of acute ischemic stroke and fifty were age- and gender-matched healthy controls. Serum uric acid level was estimted by photometry method at the time of admission. Hyperuricemia was defined as the serum uric acid level of more than 6 mg/dl. Mean serum uric acid levels in cases and controls were 5.996 ±1.99 mg/dl and 5.042 ±0.91 mg/dl, respectively. Hyperuricemia was present in 23 (46%) patients with ischemic stroke and in 10 (20%) controls. Among ischemic stroke patients, the frequency of hyperuricemia was significantly higher than in controls (p-value =0.006, Odds Ratio (OR) =3.41.) Conclusion:Serum uric acid was found significantly elevated in ischemic stroke patients versus controls with 3.41 times more risk of having hyperuricemia in ischemic stroke patients. Key Words: Hyperuricemia, Ischemic stroke, Serum uric acid (SUA).

Serum Uric Acid Level in Preeclamptic Women Determine the Severity of Preeclampsia

Background: Serum uric acid is a relatively insoluble metabolite of purine metalolism which is mainly secreted by the kidneys and the rate is dependant on renal blood flow . It increases in preeclampsia and studies show it may be marker of severe preeclampsia.&#x0D; Methods and materials: This cross sectional study was conducted in Dhaka Medical College Hospital in eclampsia ward of gynae &amp; Obs department during the period from January 2010 to December 2011 with the objective to determine the serum uric acid level in preeclampsia, to compare the serum uric acid level between mild and sever preeclampsia and to find out any relationship of the serum uric acid level with hypertension in preeclampsia. The study group composed of 92 diagnosed case of preeclampsia patient. Out of the 92 cases, 42 had mild preeclampsia (group-A) and 50 had severe preeclampsia (group B).&#x0D; Result: The results of the study showed that the mean serum uric acid level was significantly higher in severe preeclampsia (6.91+1.02) compared to mild preeclampsia (4.99 + 0.80) and there is a positive and significant relationship of serum uric acid level with severity of hypertension in preeclampsia (p&lt;.0001).&#x0D; Conclusion: There is significant association between serum uric acid level and severity of hypertension in Preeclampsia.&#x0D; Bangladesh J Obstet Gynaecol, 2017; Vol. 32(2) : 67-72

Chronic obstructive pulmonary disease (COPD) is associated with a higher level of serum uric acid. A systematic review and meta-analysis.

Recent studies have suggested that patients with chronic obstructive pulmonary disease (COPD) may have a higher level of serum uric acid compared with individuals without COPD, although the data are still limited. The current systematic review and meta-analysis was conducted to summarize all available data. A systematic review was performed using the MEDLINE and EMBASE databases from their inception to July 2019. Studies that were eligible for the meta-analysis must have consisted of two groups of participants, patients with COPD and individuals without COPD. The eligible studies must have reported either mean or median level of serum uric acid and its standard deviation (SD) or interquartile range of participants in both groups. Mean serum uric acid level and SD of participants in both groups were extracted from each study and the mean difference (MD) was calculated. Pooled MD was then computed by combining MDs of each study using random effects model. A total of eight studies with 1,612 participants met the eligibility criteria and were included in the data analysis. The serum uric acid level among patients with COPD was significantly higher than individuals without COPD with the pooled MD of 0.91 mg/dL (95% CI: 0.45-1.38; I2 = 89%). The current study found a significantly higher level of serum uric acid among patients with COPD than individuals without COPD.

P1744EFFECT OF TREATMENT WITH ALLOPURINOL ON BLOOD PRESSURE, CREATININ CLEARENCE AND PROTEINURIA IN ADULT RENAL ALLOGRAFT RECIPIENTS: A RANDOMIZED CONTROLLED TRIAL

Abstract Background and Aims Hyperuricemia has been associated with the development of hypertension, cardiovascular, and renal disease. However, there is no data about the effect of lowering uric acid level on hypertension, renal function, and proteinuria in renal transplant patients. We therefore conducted a prospective study to investigate the benefits of allopurinol treatment in renal transplant patients and to investigate indirectly its effect on graft survival. Method A total of 105 Renal transplant recipients(RTRs) were included in this study. Patients were randomized to receive either placebo (n=51) or 300 mg/day allopurinol (n=54). We have examined uric acide, urinary albümin/Cr ratio, eGFR, CRP and blood pressure before and 24 weeks later after treatment in both group. Results In the allopurinol group, the mean serum uric acid levels, eGFR, creatinine urinary albümin/Cr ratio significantly improved(P &amp;lt; 0.001). However, blood pressure, CRP not statistically significant (P &amp;gt; 0.05). No correlation was observed between changes in uric acide and changes in CRP, or blood pressure in the allopurinol group. No significant changes were observed in the control group (P &amp;gt; 0.05). Multivariable regression analysis showed that uric acide was positively correlated with UACR (r= 0,473, β = 0.021, P = 0.002) and negatively correlated with eGFR ( r= -0554 β = 0.016, P = 0.001) in RTRs. Conclusion We bring indirect evidence that hyperuricemia increases urinary albümin/Cr ratio, and decreases eGFR. Hence, management of hyperuricemia may prevent the progression of renal disease, even in patients with normal renal function, suggesting that early treatment with allopurinol should be an important part of the management of renal transplant recipients. Long-term follow-up studies are warranted to identify the benefits of uric acid management on renal function and proteinuria.

P1597USE OF FEBUXOSTAT IN HYPERURICEMIC PATIENTS UNDERGOING DIALYSIS: TOLERABILITY AND EFFICACY IN INDIAN POPULATION

Abstract Background and Aims Hyperuricemia is associated with increased vascular events in chronic kidney disease (CKD). Febuxostat is an effective alternative treatment in this subset but there is scarcity of data on its use in patients undergoing dialysis. The aim of our study was to evaluate efficacy and safety profile of febuxostat in hyperuricemic Indian patients on dialysis. Method Fifty four patients with CKD stage 5D and hyperuricemia were included in the study from Jul 2018 to Mar 2019. Febuxostat was started and patients followed-up over 6 months for decline in uric acid and any adverse events. Results Out of 54 cases, 30 were males (55.56%). Mean age was 51.28±16.9 years. Thirty two cases were diabetic (59.26) and all cases were on two or more antihypertensives. Nine cases were suffering from gout at time of inclusion and mean serum creatinine in these cases was 10.47 mg/dl. Symptomatic cases responded to treatment within 2 weeks of therapy. Mean serum uric acid level at 3 months post-treatment (4.65±0.96 mg/dL) was significantly reduced compared from pre-treatment level (8.34± 1.18 mg/dL) [p&amp;lt;0.01]. Serum uric acid level remained significantly low for 6 months without deterioration in eGFR. Blood pressure remained well controlled during therapy period and only four cases required increment of antihypertensive medication. Out of 54 cases, five stopped medication due to adverse events. Out of them, three cases were on peritoneal dialysis. Three cases developed skin rash which subsided once drug was withheld. Most common side effect was nausea (7/54) and headache (6/54). Conclusion Febuxostat at a low dose of 40 mg/dl is well tolerated among dialysis population. It effectively declines serum uric acid level. Gastrointestinal side effects are most common adverse event which corresponds to non-dialysis population. There was no higher risk of skin rash or other major adverse event in this subset. It is also worth mentioning that hyperuricemia is associated with significant vascular events and all cases included in study were hypertensive.

Hyperuricemia is associated with metabolic syndrome in the community very elderly in Chengdu

Hyperuricemia is a risk factor for cardiovascular metabolic diseases. However, in the very elderly, the relationship between hyperuricemia and the metabolic syndrome (MetS) is not yet clear. This study was aimed to investigate the potential association between hyperuricemia and MetS in community very elderly in Chengdu. In this cross-sectional study, 1056 very elderly in the community were enrolled. Serum uric acid (SUA), fast plasma glucose, triglycerides and high–density lipoprotein cholesterol were measured, and then MetS components were calculated. Logistic regression models were used to explore risk factors for MetS in the very elderly. Finally, 1035 participants were included in analysis whose ages ranged between 80 and 100 with a mean age of 83.6 ± 3.4 years. The mean SUA level was 356.2 ± 95.0 µmol/L. The estimated prevalence of MetS in the very elderly was 25.0% vs. 21.6% (international diabetes federation (IDF) criteria vs. Chinese guideline), which was significantly higher for women (IDF criteria:17.3% in men vs 33.6% in women, p < 0.001). Logistic regression has found that participants with hyperuricemia (SUA level > 416 µmol/L in men and > 357 µmol/L in women) had a higher risk (IDF criteria: odds ratio (OR): 2.136, 95% confidence interval(CI): 1.525–2.993, p < 0.001. Chinese guideline: OR: 1.769, 95%CI: 1.249–2.503, p = 0.001) of MetS in very elderly Chinese. MetS is common in the community of very elderly Chinese in Chengdu. Hyperuricemia is associated with MetS in general very elderly and lifestyle changing should also be considered in the very elderly.

Serum Uric Acid is Associated with Renal Prognosis of Lupus Nephritis in Women but not in Men

Lupus nephritis (LN) is a major complication of systemic lupus erythematosus. Early intervention in lupus nephritis improves prognosis. There is an association between hyperuricemia and lupus nephritis; nevertheless, the sex-specific role of uric acid in lupus nephritis remains unclear. We retrospectively analyzed 578 patients diagnosed with LN by renal biopsy. We determine the relationship of serum uric acid to progression of LN using Kaplan–Meier survival analyses and Cox proportional hazards models. The primary end point was LN progression defined as the initiation of dialysis or kidney transplantation. Men had higher mean serum uric acid levels than did women. Every 1 mg/dL increase in baseline uric acid level increased the risk of LN progression by 15.1%. The serum uric acid level was an independent risk factor for LN progression in women (hazard ratio [HR], 1.158; confidence interval [CI], 1.018–1.317; p = 0.028) but not in men (HR, 1.499; CI, 0.964–2.331; p = 0.072). Sensitivity analysis involving serum uric acid terciles generated consistent and robust results. Serum uric acid level was an independent risk factor for LN progression in women but not in men.

Estimation of Serum Uric Acid Level in Preeclamptic Women Determine the Severity of Preeclampsia

Background: Serum uric acid is a relatively insoluble metabolite of purine metalolism which is mainly secreted by the kidneys and the rate is dependant on renal blood flow. It increases in preeclampsia and studies show it may be a marker of severe preeclampsia.&#x0D; Objective: To determine the serum uric acid level in preeclampsia, to compare the serum uric acid level between mild and sever preeclampsia and to find out any relationship of the serum uric acid level with hypertension in preeclampsia.&#x0D; Methods and materials: This cross sectional study was conducted in Dhaka Medical College Hospital in eclampsia ward of Gynae &amp; Obs department during the period from January 2010 to December 2011. This study group composed of 92 diagnosed case of preeclampsia patient. Out of the 92 cases, 42 were mild preeclampsia and 50 were severe preeclampsia.&#x0D; Result: The results of the study showed that the mean serum uric acid level was significantly high in severe preeclampsia compared to mild preeclampsia and there is a positive and significant relationship of serum uric acid level with hypertension in preeclampsia.&#x0D; Conclusion: There is significant association between serum uric acid level and hypertension in Preeclampsia.&#x0D; Anwer Khan Modern Medical College Journal Vol. 11, No. 1: Jan 2020, P 35-40

A STUDY OF SERUM URIC ACID LEVELS IN PREECLAMPSIA

Background: To Study Serum Uric Acid level elevation in Hypertensive Disorders of Pregnancy.&#x0D; Methods: 50 Patients diagnosed as having Pre-eclampsia with age between 18-37 years and 50 controls with similar age group.&#x0D; Results: The mean serum uric acid level in control group was 3.41 ± 0.62 and in patient 7.01 ± 0.58 which was statistically significant (p =0.001).&#x0D; Conclusion: Serum uric acid levels were significantly higher in preeclampsia could be a useful indicator of fetal complication in preeclampsia patients.&#x0D; Keywords: serum uric acid, preeclampsia, laboratory.

Serum Uric Acid Level in Primigravidae with Pre-Eclampsia:A Case Control Study from Karnataka

Introduction:&nbsp;Pregnancy inducedhypertension is an exclusive condition affecting 10% ofpregnant women. The study of uric acid in serum is an interesting problemespecially in normal pregnancy and pregnancy inducedhypertension (PIH).&nbsp;Objective: To compare the changes of serum uric acid level in healthy non pregnant, PIH and normotensive pregnant women.&nbsp;Methodology: Cross sectional observational study conducted in the Obstetrics and Gynecology department, hospital, Navodaya medical college , Raichur, Karnataka involving 30 each pregnant, PIH and non-pregnant women. Serum uric acid levels were measured and analysed the data using SPSS 23 version software.&nbsp;Results: Comparison ofmean serum uric acid level in pregnant normotensive (4.14±1.05) and in PIH women (6.03±1.61) was found significant. Comparison of mean serum uric acid level in pregnant normotensive women (4.14±1.05) and in non pregnant women ( 3.39±0.5) found significant. Mean serum uric acid level in PIH women was 6.03±1.61 whereas in non pregnant women was 3.39±0.5 (p&lt;0.001).&nbsp;Conclusion:Serum uric acid level is at higher side in PIH women as compared to pregnant normotensives and non pregnant women in our study.

Is the increase of uric acid associated with the components of the metabolic syndrome?

Summary Objectives: There is increasing evidence that metabolic syndrome (MetS) may be associated with increased uric acid levels. Previous studies indicate that hyperuricaemia is an independent risk factor for cardiovascular disorders. We sought to determine the association of serum uric acid (SUA) with MetS components and other cardiovascular risk factors among middle aged Lithuanians with MetS. Design and methods: A cross-sectional study was conducted in 2018. A total of 705 subjects aged 40 to 65 years with MetS diagnosed using NCEP ATP III criteria were included. None of the participants had previously diagnosed cardiovascular, cerebrovascular, peripheral artery or end-stage oncological disease. Blood tests and all anthropometric measurements were obtained using standard methods. Subjects were divided into 2 groups: with hyperuricaemia and without hyperuricaemia. Results: Hyperuricaemia was found in 33.3% of subjects. Mean serum uric acid level increased as the number of metabolic factors increased. Participants with hyperuricaemia had abnormal waist circumference (p &lt; 0.001), higher systolic (p = 0.001) and diastolic blood pressure (p = 0.003), higher levels of triglycerides and, lower levels of high-density lipoprotein cholesterol (p &lt; 0.001). Subjects in hyperuricaemia group were more likely to be alcohol users (p = 0.034), to have diabetes (p = 0.02) and higher body mass index (p &lt; 0.001). Their creatinine levels were statistically significantly higher (p &lt; 0.001). Conclusions: Our analysis showed that serum uric acid is associated with MetS and other cardiovascular risk factors. The study found a statistically significant association with the four out of five components of the MetS (excluding plasma glucose) as well as with alcohol consumption, and renal function indicators (creatinine, eGFR).

Maternal Serum Uric Acid Levels and Adverse Pregnancy Outcomes in Women with Hypertensive Disorders of Pregnancy

Introduction: Hypertensive Disorders of Pregnancy (HDP) are the major cause of maternal morbidity and mortality worldwide. The maximum burden of maternal mortality and morbidity is due to HDP and its related complications which is further followed by obstetric haemorrhage, pre-existing medical diseases, infections and abortions. Aim: To study the association between the serum uric acid level in hypertensive pregnant women and their association with maternal and foetal morbidity and mortality. Materials and Methods: It was a prospective observational study conducted at BLDE (Deemed to be) University, Shri BM Patil Medical College Hospital and Research Centre, Vijayapura, Karnataka, India from January to June 2019. A total of 165 pregnant women with HDP were included (44 (27%) had Gestational Hypertension (GH); 86 (52%), Pre-eclampsia (PE) and 35 (21%) eclampsia) in each group in the study and they were subjected for obstetric history, examination and laboratory evaluation. The laboratory evaluation included complete blood count, liver function test, renal function test, serum uric acid level and urine albumin, sugars and microscopy. The maternal and foetal outcomes were measured, which included mode of delivery, Neonatal Intensive Care Unit (NICU) admission, neonatal outcomes in terms of preterm or term delivery, intrauterine death, fresh still born, neonatal deaths. Results: A total of 165 cases with HDP were enrolled in the study. Mean serum uric acid level in GH, PE and eclampsia group was 5.13±1.32, 5.34±1.4, 6.05±1.67, respectively. A total of 118 participants presented at term and 47 were preterm (11 in GH, 20 in PE and 16 in eclampsia group). About 103 (62.42%) had vaginal delivery and 62 (31.51%) underwent caesarean section (14 in GH, 28 in PE and 20 in eclampsia group). All the perinatal deaths occurred were in women with PE (n=5) and eclampsia (n=2) and was not statistically analysed. Conclusion: Present study shows that increased levels of maternal serum uric acid levels were associated with PE and eclampsia compared to GH patients and were associated with adverse foetal outcomes and increase in the instrumental and operative interventions.